Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) insider Joseph P. Lyssikatos sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $16.42, for a total value of $197,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Joseph P. Lyssikatos also recently made the following trade(s):

  • On Monday, January 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.85, for a total value of $190,200.00.
  • On Thursday, December 21st, Joseph P. Lyssikatos sold 20 shares of Enliven Therapeutics stock. The shares were sold at an average price of $13.00, for a total value of $260.00.
  • On Tuesday, December 19th, Joseph P. Lyssikatos sold 200 shares of Enliven Therapeutics stock. The shares were sold at an average price of $13.00, for a total value of $2,600.00.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock remained flat at $16.67 during trading on Monday. The company had a trading volume of 48,423 shares, compared to its average volume of 124,761. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $24.22. The company’s 50-day moving average price is $15.07 and its 200 day moving average price is $13.92. The firm has a market cap of $686.97 million, a PE ratio of 5.21 and a beta of 1.05.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in ELVN. Barclays PLC purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $158,000. Bank of New York Mellon Corp purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $335,000. Tower Research Capital LLC TRC purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $36,000. Citigroup Inc. bought a new position in shares of Enliven Therapeutics in the first quarter worth $247,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Enliven Therapeutics in the first quarter worth $217,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Featured Articles

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.